Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is ...

Canada Gairdner Awards recognize the world’s most accomplished researchers whose work is improving our understanding of human ...

Dr. Michael Welsh, a longtime University of Iowa physician-scientist, has been named a 2025 recipient of the prestigious ...

When I was first diagnosed with CF, I wasn’t supposed to live past the age of 8. Then Trikafta gave me the chance for a future I wasn’t prepared for. I’ve built a new life for myself and learned to ...

which is the threshold for a cystic fibrosis diagnosis, with 86% of patients on the new drug hitting that target at week 25 versus 77% of the Trikafta group. There was also an approximately ...

The Gairdner Foundation is pleased to announce the 2025 Canada Gairdner Award laureates, recognizing some of the world's most significant biomedical and global health research and discoveries.

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

Vertex Pharmaceuticals today announced that the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has granted consent for the expanded use of ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high estimate of $567.00, and a low estimate of $407.00. This upward trend is ...

With cystic fibrosis treatments – led by Trikafta (marketed as Kaftrio in Europe and other regions) -- currently accounting for over 93% of total revenue, these two potentially multibillion ...

Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is driving record sales. The company is also poised to benefit from two ...